智通财经APP获悉，周四，Kardigan(KARD.US)登陆美股市场，开盘股价涨超25%，报20.1美元。IPO价格为16美元。Kardigan是一家专注于心血管疾病创新疗法研发的临床阶段生物技术公司，致力于开发用于治疗心律失常及其他心脏疾病的新一代精准药物。公司核心产品管线聚焦于调节心脏电生理功能，通过靶向特定离子通道改善异常心律问题，目标是在提升疗效的同时降低传统抗心律失常药物带来的安全性风险。目前，公司多项候选药物仍处于临床开发阶段，尚未实现商业化收入。
智通财经APP获悉，周四，Kardigan(KARD.US)登陆美股市场，开盘股价涨超25%，报20.1美元。IPO价格为16美元。Kardigan是一家专注于心血管疾病创新疗法研发的临床阶段生物技术公司，致力于开发用于治疗心律失常及其他心脏疾病的新一代精准药物。公司核心产品管线聚焦于调节心脏电生理功能，通过靶向特定离子通道改善异常心律问题，目标是在提升疗效的同时降低传统抗心律失常药物带来的安全性风险。目前，公司多项候选药物仍处于临床开发阶段，尚未实现商业化收入。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.